Lessons Learned: What the Cyclospora Outbreak Teaches Us About the Importance of Accurate Diagnostics

As of Sept. 1, 2026, the CDC reported 18,445 laboratory-confirmed cases of cyclosporiasis, 990 hospitalizations, and 2 deaths. This multi-state outbreak far exceeded previous seasonality in the occurrence of this parasite across the U.S., with 1,180 laboratory-confirmed cases from May 1 to Aug. 31, 2025.

This summer’s Cyclospora outbreak brought with it an opportunity for learning best practices and a reminder that surveillance monitoring and community data can help healthcare providers, municipalities, and government agencies be ready for the next outbreak. 

Identifying the illness accurately and early on is key to effective care. With point-of-care testing available via the BIOFIRE^® TORCH^® and BIOFIRE^® SPOTFIRE^® Gastrointestinal (GI) Panels, patients could receive an accurate diagnosis early and begin treatment sooner. 

“Timely pathogen identification is crucial, making it important for labs and clinical teams to have the right test, at the right time, wherever the patient is,” states John Osiecki, Vice President, Medical Affairs, bioMérieux. “Because these diagnostic panels test for 22 of the most common gastrointestinal pathogens from a single sample in about an hour, they can help guide treatment decisions, support public health surveillance, and inform an appropriate response. While there are several FDA-cleared multiplex panels that are commercially available for clinical diagnostic testing, not all of them include Cyclospora as a target.”

bioMérieux's 22-plex BIOFIRE^® FILMARRAY^® Gastrointestinal (GI) Panel and 11-plex BIOFIRE^® FILMARRAY^® Gastrointestinal (GI) Panel Mid are built on proven syndromic molecular technology that delivers results in about one hour. Each panel covers a broad range of bacterial, viral, and parasitic targets, including Cyclospora cayetanensis, E. coli, norovirus, Salmonella, and Campylobacter. With these multiplex assays, labs and clinical teams may not only optimize antimicrobial and other treatment decisions but also offer that care across outpatient and hospital-based settings. Unlike many causes of acute gastroenteritis, targeted antimicrobial therapy is recommended for Cyclospora and can significantly shorten the duration of illness.

BioFire Defense, a bioMérieux company, offers wastewater surveillance options available to public health officials for the monitoring and identification of potential outbreaks before they occur. 

Wastewater monitoring surveillance can help public health organizations, labs, and community officials understand what pathogens are currently circulating in their community. The company’s WATCHFIRE^™ solution, which runs on the benchtop BIOFIRE^®FILMARRAY^® TORCH system, simplifies the traditional wastewater monitoring process.   

This summer, data from the WATCHFIRE^™ Gastrointestinal Panel, which tests for Cyclospora cayetanensis, was aggregated on the cloud-based FIREWORKS^™ platform for analysis and monitoring.

Together, WATCHFIRE^® and FIREWORKS^® can support more robust public health monitoring and preparedness as municipalities and organizations analyze data. 

In turn, data from SPOTFIRE and TORCH diagnostic testing is anonymized and aggregated to provide national and regional trend data. FIREWORKS is a centralized platform with real-time insights into system performance and pathogen trends available to healthcare providers and laboratories. 

Publicly available data on SyndromicTrends.com can also be helpful for understanding what pathogens are currently circulating in the United States. 

Jay Jones, Vice President, Data Science, bioMérieux, said, “We share these trends publicly on the FIREWORKS website to support community preparedness, outbreak awareness, and informed resource planning.”

FIREWORKS is a centralized platform for real-time insights into system performance and pathogen trends, and it is viable with BIOFIRE^® TORCH Systems, including both wastewater surveillance WATCHFIRE® and the clinical BIOFIRE^® FILMARRAY^® Gastrointestinal Panels. 

Its Trends dashboard collects current and historical test results from participating BIOFIRE® FILMARRAY^® and BIOFIRE® SPOTFIRE^® systems. This data helps community health officials and healthcare teams to identify emerging trends and evaluate potential public health risks. 

Just as the Cyclospora outbreak is winding down, communities are going back to school. With it, we’re already seeing a predictable uptick in rhinovirus detection on SyndromicTrends.com.

Now is the time for public health agencies, government groups, and healthcare providers to prepare for the respiratory season ahead using the lessons of fast, accurate detection to provide effective prevention and treatment from this summer’s outbreak.